R1 RCM

RCM · NASDAQ

Price unavailable right now.

No price history for this range.

RCM analyst rating

This isn't available right now. Refresh to try again.

The case for and against

Updated Nov 20, 2024

Bull case

R1 RCM Inc. is transitioning its annual new NPR deployment capacity to $9 billion, reflecting management's confidence in long-term demand and competitive positioning. The company is seeing positive fundamental trends, particularly with a better-than-expected Q3 performance, driven by incentive fees that indicate client-level health. With anticipated EBITDA and EPS growth nearly double the group average over the next three years, as well as an expanding client base and higher EBITDA margins expected post-2024, R1 RCM is well-positioned for sustained revenue growth in the $115 billion RCM market.

Bear case

R1 RCM Inc experienced a slight increase in 3Q23 adjusted EBITDA, reporting $161.5 million, which was approximately 3% above consensus estimates; however, the company has lowered its 2023 revenue guidance to a range of $2,255 million to $2,275 million, reflecting a decrease of about 2% at the midpoint. This downward adjustment is compounded by potential risks, including client shrinkage, the financial viability of its customer base, and challenges in cross-selling opportunities post-acquisition of Cloudmed, all of which could negatively impact future revenue generation and profitability. Additionally, increased competition, customer concentration risks, and ongoing legislative changes pose significant challenges for R1 RCM, contributing to a deteriorating outlook for its stock.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.